SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-18-014956
Filing Date
2018-08-08
Accepted
2018-08-08 17:04:22
Documents
74
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20180630_10q.htm 10-Q 1111513
2 EXHIBIT 31.1 ex_120089.htm EX-31.1 9342
3 EXHIBIT 31.2 ex_120090.htm EX-31.2 9355
4 EXHIBIT 32.1 ex_120091.htm EX-32.1 4588
5 EXHIBIT 32.2 ex_120092.htm EX-32.2 4634
  Complete submission text file 0001437749-18-014956.txt   7266416

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20180630.xml EX-101.INS 1708299
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20180630.xsd EX-101.SCH 61138
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20180630_cal.xml EX-101.CAL 47032
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20180630_def.xml EX-101.DEF 554109
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20180630_lab.xml EX-101.LAB 385123
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20180630_pre.xml EX-101.PRE 569782
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 181002258
SIC: 2835 In Vitro & In Vivo Diagnostic Substances